HUTCHMED (China) (H7T2) Price & Analysis
H7T2 Stock Chart & Stats
- Day’s Range
- EUR 2.22 - EUR 2.28
- 52-Week Range
- EUR 1.65 - EUR 2.86
- Previous Close
- EUR 2.26
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 2.06B
- Enterprise Value
- EUR 4.72B
- Total Cash (Recent Filing)
- EUR 1.38B
- Total Debt (Recent Filing)
- EUR 94.51M
- Price to Earnings (P/E)
- 143.2
- Beta
- 0.25
- Next Earnings
- Mar 04, 2027
- EPS Estimate
- 0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage gives HUTCHMED financial flexibility to continue funding research, clinical development and commercialization while absorbing operating volatility. A strong equity base also reduces dependence on borrowing and supports the company’s ability to pursue growth opportunities across its oncology pipeline.
Strong Clinical Efficacy
The SANOVO results strengthen the clinical case for Orpathys plus Tagrisso in a defined NSCLC population. Durable progression-free and overall-survival benefits can improve regulatory and commercial prospects, expand product adoption, and reinforce HUTCHMED’s oncology competitive position.
Integrated Partnering Model
Control across discovery, development, regulatory work and commercialization can help HUTCHMED retain more strategic control over its medicines while using partners to extend international reach. This model supports multiple routes to product revenue, milestones and royalties as assets mature.
Bears Say
Negative Core Profitability
Negative operating margins indicate that the core business is not yet converting revenue into durable operating profit. Positive net income alongside negative EBIT and EBITDA suggests earnings quality is weak, leaving future profitability dependent on improving commercial economics and reducing reliance on non-operating items.
Unstable Cash Generation
Volatile cash generation makes it harder to assess HUTCHMED’s ability to self-fund research, trials and commercialization through the cycle. A recent reversal from positive cash flow to materially negative annual results could increase dependence on the balance sheet or external funding if it persists.
Weak Growth Trend
The recent contraction in revenue and sharp EPS deterioration point to limited earnings stability and weak momentum in the existing business base. Unless pipeline launches, product uptake or partnerships offset this trend, lower scale can constrain operating leverage and delay consistent profitability.
HUTCHMED (China) News
H7T2 FAQ
What was HUTCHMED (China) ’s price range in the past 12 months?
What is HUTCHMED (China) ’s market cap?
When is HUTCHMED (China) ’s upcoming earnings report date?
How were HUTCHMED (China) ’s earnings last quarter?
Is HUTCHMED (China) overvalued?
Does HUTCHMED (China) pay dividends?
What is HUTCHMED (China) ’s EPS estimate?
How many shares outstanding does HUTCHMED (China) have?
What happened to HUTCHMED (China) ’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HUTCHMED (China) ?
What is the TipRanks Smart Score and how is it calculated?
HUTCHMED (China) Stock Smart Score
Company Description
HUTCHMED (China)
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. Its operations are structured into two main segments: Oncology/Immunology and Other Ventures. The company boasts an extensive pipeline of drug candidates. Key assets include Savolitinib, an inhibitor developed for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Fruquintinib targets CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a broad spectrum of gastrointestinal and solid tumors. Another prominent compound, Surufatinib, is indicated for various neuroendocrine tumors (NETs) including pancreatic and non-pancreatic types, alongside biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and other solid tumors. Further pipeline assets feature HMPL-523, a spleen tyrosine kinase (Syk) inhibitor for treating hematological cancers and certain chronic immune diseases; HMPL-689, an inhibitor specifically targeting the PI3Kd isoform; and Tazemetostat, an EZH2 inhibitor utilized in the treatment of specific epithelioid sarcoma and follicular lymphoma patients. The company's development efforts also encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase (BTK) inhibitor; HMPL-453, aimed at intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; HMPL-653, developed for metastatic solid tumors and tenosynovial giant cell tumors; and the inhibitors Epitinib (HMPL-813) and Theliatinib (HMPL-309). HUTCHMED has forged strategic collaboration agreements with a number of significant pharmaceutical entities, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company, originally known as Hutchison China MediTech Limited, officially changed its name to HUTCHMED (China) Limited in May 2021.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Chig Fung Cheng
- Employees
- 1,796
- Website
- www.hutch-med.com
- Address
- HK
HUTCHMED (China) (H7T2) Earnings & Revenues
H7T2 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 2 | 10 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 4 | 0 | 8 |